| 张燕,王曙霞,马守原,等.老年非瓣膜性心房颤动患者服用利伐沙班的有效性及安全性研究[J].中国临床保健杂志,2019,22(5):588-590. |
| 老年非瓣膜性心房颤动患者服用利伐沙班的有效性及安全性研究 |
| Clinical effect of rivaroxaban among elderly patients with non-valvular atrial fibrillation |
| 投稿时间：2018-11-19 |
| DOI：10.3969/J.issn.1672-6790.2019.05.004 |
| 中文关键词: 心房颤动 利伐沙班 有效性研究 药物相关性副作用和不良反应 老年人 |
| 英文关键词: Atrial fibrillation Rivaroxaban Validation studies Drug-related side effects and adverse reactions Aged 〖FL |
| 基金项目:国防科技创新特区项目(17-163-15-XJ-001-004-03) |
|
| 摘要点击次数: 6327 |
| 全文下载次数: 4956 |
| 中文摘要: |
| 目的 探讨老年非瓣膜性心房颤动患者给予利伐沙班的临床用药安全性及有效性。方法 选取≥60岁使用华法林抗凝治疗的非瓣膜性心房颤动患者154例,改为利伐沙班抗凝治疗,15毫克/次,1次/天。观察随访时间内患者出血及栓塞事件发生情况。结果 服用利伐沙班后患者血肌酐(Ccr)较前升高,不良事件发生率明显低于服用前,差异有统计学意义(P<0.05)；其他凝血、血常规、肝功能指标相对稳定,差异无统计学意义(P＞0.05)。结论 利伐沙班在非瓣膜性心房颤动抗凝治疗中与华法林相比呈现其安全性及有效性。 |
| 英文摘要: |
| Objective To analyze the clinical safety and effectiveness of rivaroxaban in elderly patients with atrial fibrillation.Methods A total of 154 patients over 60 years old with non-valvular atrial fibrillation in our hospital were enrolled in this study.They switched anticoagulant therapy from warfarin to rivaroxaban,with a dose of 15 mg once daily.The clinical efficacy,bleeding and embolism events were observed during the follow-up period.Results The Ccr increased significantly with the treatment of rivaroxaban,and the incidence of adverse events was significantly lower than before (P<0.05).Other coagulation indexes,blood routine indexes and liver function indexes were relatively stable,showing no significantly difference (P>0.05).Conclusion Rivaroxaban is its safety and effectiveness in anticoagulant therapy for patients with non-valvular atrial fibrillation. |
|
查看全文
|
| 关闭 |